PTIX — Protagenic Therapeutics, Inc.\new
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1022899 ·
Last close
$0.47
Market Cap
$842.5K
52W High
$1.20
52W Low
$0.42
ADV30
7,513
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -925,103 | 2,210,769 | 4,431,101 | 2,212,646 | 6,823,789 |
| Sep 2025 | 0 | — | -1,113,864 | -869,496 | 5,002,847 | 2,722,451 | 9,703,412 |
| Jun 2025 | 0 | — | -1,208,374 | -5,057,523 | 6,488,200 | 4,096,189 | 10,462,212 |
| Mar 2025 | 0 | — | -1,448,108 | -1,440,005 | 988,650 | 872,960 | 1,076,979 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,140,350
Investing CF
$943,180
Financing CF
$4,510,070
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.45
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-9,113,856
Inventory
$1,074
Receivables
$41,523
ST Investments
$0
EBIT TTM
$-8,305,871
Pretax Income TTM
$-5,156,255
Interest Exp TTM
$238,727
Analysts
—
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2024 | 0 | -5,700,950 | -5,525,344 | 1,955,913 | 942,759 | — | -4,216,517 |
| Dec 2023 | 0 | -4,526,974 | -5,000,497 | 4,323,369 | 655,252 | — | -3,703,776 |
| Dec 2022 | 0 | -3,557,788 | -3,555,505 | 8,037,420 | 1,119,862 | — | -1,993,814 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.58
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EVFM | Evofem Biosciences, Inc. | $874.7K | $0.01 | — |
| SKVI | SKINVISIBLE, INC. | $924.6K | $0.17 | — |
| ATXI | AVENUE THERAPEUTICS, INC. | $757.8K | $0.23 | — |
| OWPC | One World Products, Inc. | $720.7K | $0.01 | — |
| EMMA | Emmaus Life Sciences, Inc. | $701.9K | $0.01 | — |
News headlines (Yahoo Finance, 1h cache)
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
2026-05-19 12:15 · Yahoo
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
2026-04-23 12:15 · Yahoo
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
2026-03-17 12:00 · Yahoo
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
2026-03-10 12:00 · Yahoo
Results from Phase 1 Multiple-Dose Study of PT00114
2025-12-09 13:46 · Yahoo
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
2025-11-27 08:45 · Yahoo
Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study
2025-11-13 13:22 · Yahoo
Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
2025-08-22 21:25 · Yahoo
Sector Update: Health Care Stocks Mixed Late Afternoon
2025-08-21 20:04 · Yahoo
Top Midday Gainers
2025-08-21 17:54 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.